Do drugs that target mTOR generate CCN2-mediated fibrogenic side effects?

Area of Science:

• Molecular biology
• Cellular signaling
• Fibrosis research

Background:

• The target of rapamycin (mTOR) pathway is a key regulator of cell growth, proliferation, and survival.
• mTOR has been investigated as a therapeutic target for conditions including cancer, transplantation, and lung fibrosis.
• Paradoxically, mTOR inhibition has been linked to adverse profibrotic side effects in some contexts.

Purpose of the Study:

• To elucidate the mechanisms underlying the profibrotic side effects of mTOR targeting.
• To reconcile the seemingly contradictory roles of mTOR in disease and fibrosis.
• To provide insights into the safe and effective therapeutic application of mTOR inhibitors.

Main Methods:

• Review of recent scientific literature on mTOR signaling and fibrosis.
• Analysis of experimental data linking mTOR activity to fibrotic processes.
• Comparative analysis of different mTOR inhibitors and their effects.

Main Results:

• Emerging evidence suggests that mTORC2 signaling may play a critical role in mediating profibrotic responses.
• Differential effects of mTORC1 and mTORC2 inhibition on fibrogenesis are being identified.
• Specific cellular contexts and molecular crosstalks are being explored to explain the paradoxical effects.

Conclusions:

• Understanding the dual role of mTOR in disease and fibrosis is crucial for therapeutic development.
• Careful consideration of mTORC1 vs. mTORC2 inhibition may be necessary to avoid profibrotic complications.
• Further research is warranted to optimize mTOR-targeted therapies and mitigate adverse effects.